Asuka Nakata

692 citations
12 papers · 484 indexed · h-index 8
Topics
Lung Cancer Treatments and Mutations (5 papers)RNA modifications and cancer (2 papers)HER2/EGFR in Cancer Research (2 papers)
Partner nations
JapanUnited StatesBrazil

In The Last Decade

Asuka Nakata

11 papers receiving 479 citations

Peers

Asuka Nakata
Comparison fields: 5 of 54
  • Molecular Biology 368
  • Cancer Research 243
  • Pulmonary and Respiratory Medicine 152
  • Oncology 130
  • Immunology 29
Replace Jianguo Lai with:
Jianguo Lai China
Erwin Tomasich Austria
Verena Sailer Germany
Yuanhe Wang China
Evan R. Abt United States
Dian-na Gu China
Kaikai Zhao China
Apryle Seeley United States
Yang Peng China
Richard Kurupi United States
Asuka Nakata relative to Jianguo Lai China Jianguo Lai's profile →
Citations per field
00.5×9.6×
Jianguo Lai · 1×
Citations per year

Countries citing papers authored by Asuka Nakata

Since Specialization
Citations

This map shows the geographic impact of Asuka Nakata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asuka Nakata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asuka Nakata more than expected).

Fields of papers citing papers by Asuka Nakata

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asuka Nakata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asuka Nakata. The network helps show where Asuka Nakata may publish in the future.

Co-authorship network of co-authors of Asuka Nakata

This figure shows the co-authorship network connecting the top 25 collaborators of Asuka Nakata. A scholar is included among the top collaborators of Asuka Nakata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asuka Nakata. Asuka Nakata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 0
2 13
3 2
4 16
5 79
6 48
7 108
8 6
9 40
10
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs
1
11 143
12 28

About Asuka Nakata

Asuka Nakata is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 12 papers that have together received 484 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (5 papers), RNA modifications and cancer (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Cancer Research (243 citations), Molecular Biology (368 citations) and Oncology (130 citations). Asuka Nakata has collaborated with scholars based in Japan, United States and Brazil. Frequent co-authors include Noriko Gotoh, David G. Beer, Takashi Kohno, Mai Yamauchi, Andrew C. Chang, Tatsunori Nishimura, Rui Yamaguchi, Tomoyuki Higuchi, Masaharu Nomura and Ernest Nadal. Their work appears in journals such as PLoS ONE, Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026